Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences

[1]  P. Boor,et al.  The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery , 2018, Science Translational Medicine.

[2]  E. Mazzon,et al.  Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach , 2018, Oncotarget.

[3]  K. L. Monaghan,et al.  Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications , 2017, Medical sciences.

[4]  D. Bourdette,et al.  MIF and D-DT are potential disease severity modifiers in male MS subjects , 2017, Proceedings of the National Academy of Sciences.

[5]  A. Rizvanov,et al.  Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients , 2017, Front. Immunol..

[6]  L. Leng,et al.  Adoptive transfer of a novel MIF receptor (CD74+) expressing memory T cell subpopulation is sufficient to transfer inflammatory arthritis , 2017, The Journal of Immunology.

[7]  J. Araújo,et al.  Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer , 2017, Pathology & Oncology Research.

[8]  Mika Gustafsson,et al.  Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. , 2016, Cell reports.

[9]  J. Bernhagen,et al.  D‐dopachrome tautomerase in adipose tissue inflammation and wound repair , 2016, Journal of cellular and molecular medicine.

[10]  Z. Nemeth,et al.  The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders , 2016, Expert opinion on therapeutic targets.

[11]  R. Rossaint,et al.  Interaction of MIF Family Proteins in Myocardial Ischemia/Reperfusion Damage and Their Influence on Clinical Outcome of Cardiac Surgery Patients , 2015, Antioxidants & redox signaling.

[12]  G. Fingerle-Rowson,et al.  Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[13]  C. Graetz,et al.  New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. , 2015, Brain : a journal of neurology.

[14]  M. Trotter,et al.  Demyelination Causes Adult CNS Progenitors to Revert to an Immature State and Express Immune Cues That Support Their Migration , 2015, The Journal of Neuroscience.

[15]  S. Mammana,et al.  Hypomethylating Agent 5‐Aza‐2′‐deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models , 2014, Journal of cellular physiology.

[16]  R. Bucala,et al.  Targeting distinct tautomerase sites of D‐DT and MIF with a single molecule for inhibition of neutrophil lung recruitment , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  P. Popovich,et al.  Glucocorticoids and macrophage migration inhibitory factor (MIF) are neuroendocrine modulators of inflammation and neuropathic pain after spinal cord injury. , 2014, Seminars in immunology.

[18]  A. Ultsch,et al.  R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice , 2014, Journal of Neuroimmunology.

[19]  R. Bucala,et al.  HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis , 2014, The Journal of Immunology.

[20]  Jessica K. Alexander,et al.  Macrophage Migration Inhibitory Factor Potentiates Autoimmune-Mediated Neuroinflammation , 2013, The Journal of Immunology.

[21]  Jae Won Lee,et al.  Glucocorticoids attenuate septic acute kidney injury. , 2013, Biochemical and biophysical research communications.

[22]  Huiyong Sun,et al.  Current developments of macrophage migration inhibitory factor (MIF) inhibitors. , 2013, Drug discovery today.

[23]  Simon Hametner,et al.  Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.

[24]  D. Bourdette,et al.  Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects , 2013, European journal of immunology.

[25]  R. Totaro,et al.  A gender-related action of IFNbeta-therapy was found in multiple sclerosis , 2012, Journal of Translational Medicine.

[26]  R. Bucala,et al.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. , 2012, Cytokine.

[27]  C. Trautwein,et al.  Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74 , 2011, Proceedings of the National Academy of Sciences.

[28]  O. Lesur,et al.  The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF) , 2011, Proceedings of the National Academy of Sciences.

[29]  T. Gaber,et al.  Macrophage Migration Inhibitory Factor Counterregulates Dexamethasone-Mediated Suppression of Hypoxia-Inducible Factor-1α Function and Differentially Influences Human CD4+ T Cell Proliferation under Hypoxia , 2011, The Journal of Immunology.

[30]  M. Donia,et al.  Specific and Strain‐Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents , 2010, Scandinavian journal of immunology.

[31]  A. Akçalı,et al.  Association of Macrophage Migration Inhibitory Factor Gene Promoter Polymorphisms with Multiple Sclerosis in Turkish Patients , 2010, The Journal of international medical research.

[32]  M. Donia,et al.  Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis , 2010, Clinical and experimental immunology.

[33]  T. Tuller,et al.  Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells , 2009, BMC Medical Genomics.

[34]  D. Kusewitt,et al.  Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet‐B (UVB) ‐induced nonmelanoma skin cancer (NMSC) , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  H. Tohyama,et al.  A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis , 2008, Gene Therapy.

[36]  R. Bucala,et al.  Cooperative Regulation of Non-Small Cell Lung Carcinoma Angiogenic Potential by Macrophage Migration Inhibitory Factor and Its Homolog, d-Dopachrome Tautomerase1 , 2008, The Journal of Immunology.

[37]  F. Nicoletti,et al.  Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus , 2008, Journal of cellular physiology.

[38]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[39]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[40]  Harukazu Tohyama,et al.  A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. , 2007, Arthritis and rheumatism.

[41]  S. Stošić-Grujičić,et al.  Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. , 2006, International immunopharmacology.

[42]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[43]  M. Mori,et al.  Lack of macrophage migration inhibitory factor protects mice against concanavalin A‐induced liver injury , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[44]  Michael Bacher,et al.  ISO-1 Binding to the Tautomerase Active Site of MIF Inhibits Its Pro-inflammatory Activity and Increases Survival in Severe Sepsis* , 2005, Journal of Biological Chemistry.

[45]  A. Satoskar,et al.  Cutting Edge: Macrophage Migration Inhibitory Factor Is Necessary for Progression of Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.

[46]  F. Bolgert,et al.  Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain–Barré syndrome and experimental allergic neuritis , 2005, Journal of Neuroimmunology.

[47]  F. Nicoletti,et al.  Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. , 2005, Endocrinology.

[48]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[49]  M. Denkinger,et al.  In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Acute Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System , 2003, The Journal of Immunology.

[50]  J. Bernhagen,et al.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1 , 2000, Nature.

[51]  S. Kikuchi,et al.  Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet’s disease , 2000, Journal of the Neurological Sciences.

[52]  F. Nicoletti,et al.  Dichotomic effects of IFN‐γ on the development of systemic lupus erythematosus‐like syndrome in MRL‐lpr / lpr mice , 2000, European journal of immunology.

[53]  F. Nicoletti,et al.  Biphasic effect of interferon‐γ in murine collagen‐induced arthritis , 1995, European journal of immunology.

[54]  R. Tisch,et al.  Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process , 1994, The Journal of experimental medicine.

[55]  E. Rosengren,et al.  Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5,6-dihydroxyindole. , 1993, Biochemical and biophysical research communications.

[56]  Y. Al-Abed,et al.  MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. , 2011, Future medicinal chemistry.

[57]  F. Nicoletti,et al.  MIF in autoimmunity and novel therapeutic approaches. , 2009, Autoimmunity reviews.

[58]  中島 弘明.  Lack of macrophage migration inhibitory factor protects mice against concanavalin A-induced liver injury , 2006 .

[59]  F. Dhabhar,et al.  Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. , 2003, The American journal of pathology.

[60]  J. David.  Macrophage migration. , 1968, Federation proceedings.